Companies › BioNet-Asia
1 active drug program in 1 registered trial: 1 Phase 3; Vaccines.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Recombinant acellular pertussis (aP) vaccine (Pertagen®) Recombinant acellular pertussis vaccine containing genetically detoxified pertussis toxin | – | Phase 3 | Pertussis Vaccine | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06798831 | Recombinant acellular pertussis (aP) vaccine (Pertagen®) | Phase 3 | Pertussis Vaccine | Vaccines | Apr 2025 |
No annotated target.
–
Liaoning Chengda Biotechnology Beijing Minhai Biotechnology Medigen Vaccine Biologics Sinovac (Dalian) Vaccine Technology Sinovac Biotech
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.